Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines, despite a YoY revenue contraction of 13% due to strategic divestitures. Total revenue reached $70.5M vs. the $69.0M expected, and Adjusted EPS of $0.04 exceeded the $0.03 consensus. Profitability was bolstered by a strong Adjusted Gross Margin of 51% (vs. 51.6% expected) and a significant reduction in stock-based compensation. Management’s Q3 guidance for revenue ($55M-$56M) and Adjusted EBITDA suggests further sequential cooling following the Vitalware divestiture.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Health Catalyst(HCAT) the Revenue is 70.49 M (-12.68%), Beat estimate;the EBIT is -36.48 M (+1.66%), Miss estimate;the EPS is -0.55 (+6.78%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.07B12.68%
0.07B14.48%
+0.00B1.80%
EBITMiss expectations
-0.04B1.66%
-0.01B74.04%
-0.03B72.38%
EPSMiss expectations
-0.556.78%
-0.1574.58%
-0.400067.80%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf